<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FCBBA6DC-07D3-4E2F-9DE7-19209A465186"><gtr:id>FCBBA6DC-07D3-4E2F-9DE7-19209A465186</gtr:id><gtr:name>Ridgeway Research</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E4757A6E-7326-472B-9979-B47D77A65446"><gtr:id>E4757A6E-7326-472B-9979-B47D77A65446</gtr:id><gtr:name>Aberystwyth University</gtr:name><gtr:department>IBERS</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>King Street</gtr:line2><gtr:line3>Ceredigion</gtr:line3><gtr:line4>Aberystwyth</gtr:line4><gtr:line5>Dyfed</gtr:line5><gtr:postCode>SY23 2AX</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E4757A6E-7326-472B-9979-B47D77A65446"><gtr:id>E4757A6E-7326-472B-9979-B47D77A65446</gtr:id><gtr:name>Aberystwyth University</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>King Street</gtr:line2><gtr:line3>Ceredigion</gtr:line3><gtr:line4>Aberystwyth</gtr:line4><gtr:line5>Dyfed</gtr:line5><gtr:postCode>SY23 2AX</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1E58895D-AC7A-47A8-A238-60C71608E4DD"><gtr:id>1E58895D-AC7A-47A8-A238-60C71608E4DD</gtr:id><gtr:name>Scottish Executive Env and Rural Affairs</gtr:name><gtr:address><gtr:line1>Room 440</gtr:line1><gtr:line2>Pentland House</gtr:line2><gtr:line3>47 Robb's Loan</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH14 1TY</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8168D0C6-0D11-4346-8107-E5D172AFD438"><gtr:id>8168D0C6-0D11-4346-8107-E5D172AFD438</gtr:id><gtr:name>Dept for International Development DFID</gtr:name><gtr:address><gtr:line1>1 Palace Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW1E 5HE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FCBBA6DC-07D3-4E2F-9DE7-19209A465186"><gtr:id>FCBBA6DC-07D3-4E2F-9DE7-19209A465186</gtr:id><gtr:name>Ridgeway Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2733E008-1038-4FA1-9047-C8BE820A991B"><gtr:id>2733E008-1038-4FA1-9047-C8BE820A991B</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Barrett</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DC174CC3-7620-4CBE-96B4-D7F581994E90"><gtr:id>DC174CC3-7620-4CBE-96B4-D7F581994E90</gtr:id><gtr:firstName>Steve</gtr:firstName><gtr:surname>Paterson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E9112B50-D55F-483A-9647-9C2A38F2FDF6"><gtr:id>E9112B50-D55F-483A-9647-9C2A38F2FDF6</gtr:id><gtr:firstName>Joanne</gtr:firstName><gtr:otherNames>Veronica</gtr:otherNames><gtr:surname>Hamilton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/54A938AA-A43C-412E-B69C-9B0162073DBD"><gtr:id>54A938AA-A43C-412E-B69C-9B0162073DBD</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Brophy</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FH009256%2F1"><gtr:id>7F81332D-D146-42BB-801C-D82DF5C6E494</gtr:id><gtr:title>Developing a 'validation portfolio' to exploit key virulence proteins in Fasciola species for parasite control.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/H009256/1</gtr:grantReference><gtr:abstractText>The tropical liver fluke parasite Fasciola gigantica is one of the most important worm infections of livestock in Asia and Africa. The disease inflicts very significant losses especially in livestock in India, with infection levels reaching 55% in some regions. Recently-estimated costs for liver fluke induced losses associated with livestock in India fall within the range of US$1.95-4.78 billion per year. This is a huge burden to the largely agricultural Indian economy and directly impacts the productivity of large and small farm holdings alike, negatively impacting individual farmers and their families. Liver fluke infected buffalo show reduction in general health, weight gain, feed conversion efficiency and reproduction. The infective worm stage encysts on vegetation such that host animals inadvertently consume the cysts during grazing. Once in the gut, the juvenile worms hatch, burrow through the gut wall and penetrate the liver, ending up as adult worms in bile ducts where they feed on host blood, significantly diminishing the health of the animal and greatly reducing agricultural productivity. In the developed world liver fluke is mainly controlled using the chemical triclabendazole (TCBZ). This drug is an Achilles heel of liver fluke control as it is the only drug that kills both adult and pathogenic juveniles. New control strategies are urgently needed as anthelmintic resistance in parasitic worm populations is spreading globally, and agricultural communities in many parts of the developing world simply cannot afford short-lived, anthelmintic-based treatment options. Therefore, there is an urgent need to develop a cost effective, single-treatment control strategy based on vaccination. Numerous vaccine trials have been completed in liver fluke, many showing some success, but none have provided protection levels adequate for immediate commercialization. The problem is that since most leading vaccine candidates exist in large, related groups of proteins within parasites, it has been impossible to determine which is the best candidate from the group such that up until now, these decisions have not been subject to rigorous validation. To this end, this international collaborative project between laboratories in India and the UK will, for the first time, incorporate new fast throughput nucleotide and protein technologies to validate the candidate proteins and thereby assess if these leading vaccine candidates can be used to treat liver fluke parasites in different parts of the world, a key to successful commercial production. Once a vaccine target is confirmed as widely present in liver fluke populations, we will use another new technology called reverse genetics that can switch-off (or silence) a target in a parasite, and then confirm if this target is essential for parasite survival. If confirmed as important to parasite survival, we will subsequently use yeast laboratory cultures to produce the candidates for vaccine trials in livestock in India. Since this is a multi-discipline and multi-laboratory project, we have formed an International Science Advisory Board (ISAB) in order to manage and co-ordinate progress and to trouble-shoot. Members of the ISAB include a representative from a large Animal Pharmaceutical Company, a parasitologist with many years of industrial experience, a leading world authority on liver fluke vaccination and a representative from the industrial Biotechnology sector in India. The programme addresses the mission of the BBSRC, including treatment of diseases of livestock, application of new technologies and international collaboration. Validated trial vaccine(s) from this programme would form the basis for commercial development for treating liver fluke disease, and our technology strategy is directly transferable to other helminth parasites of animal and humans.</gtr:abstractText><gtr:technicalSummary>Liver fluke impose a major impact on global economies through the reduction of animal welfare and agricultural productivity. Whilst Fasciola hepatica is most common in temperate regions, Fasciola gigantica is one of the most important parasites of ruminants in the tropics. Although current control measures rely on anthelmintics, their use is financially unsustainable in developing countries and is further undermined by increasing drug resistance, leaving profound deficiencies in liver fluke control. Although a number of putative vaccine target candidates have been tested in small and large animals and shown some success, none have provided protection levels adequate for commercialization. Motivated by recent successes in RNAi and proteomics methods developed in our laboratories, this project proposes to optimise, validate and interface gene silencing and proteomic platforms for various liver fluke life stages, and to exploit these technologies as a drug/vaccine target validation portfolio. To do this, we propose the generation of a F. gigantica transcriptome to kick-start a reverse-chemotherapy/reverse-vaccinology programme whereby the superfamilies of leading virulence proteins (control targets) in fluke are probed for gene variation across pooled geographical isolates and via sampling of liver fluke adults and juveniles; variation qualified using transcriptomics would be quantified using subproteomic methods. Target proteins present in the majority of pooled geographical isolates and individuals would be validated using an integrated gene silencing/proteomics platform to select the most promising candidates. The leading validated candidates (i.e. population-abundant candidates that are functionally important and which are not compensated for by other pathways) would be tested for vaccine candidature in animals challenged with F. gigantica infections. These efforts will provide validated vaccine candidates/drug targets for future control strategies.</gtr:technicalSummary><gtr:potentialImpactText>On lead application (Prof. Maule, Queens University, Belfast)</gtr:potentialImpactText><gtr:fund><gtr:end>2013-06-09</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2010-06-10</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>285137</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ridgeway Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>biomarkers to detect parasitic fluke of livestock</gtr:description><gtr:id>AB5A63B8-D4B2-4A38-AAE5-D5CBBE82F795</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>5463234a438fb0.16591392-1</gtr:outcomeId><gtr:partnerContribution>Partner (Ridgeway Research Ltd) provides parasitic worms from livestock experimental infections and provides skills in field based immuno-assays .
Programme funded by Innovate UK Crop and Livestock Initiative from 2014.</gtr:partnerContribution><gtr:piContribution>Completed discovery biology on an immune modulator protein from liver fluke (Sigma GST - Prostaglandin synthase) delivered in extracellular like vesicles (EVs) to host cells and thus provided skills and procedures to isolate EVs to test as biomarkers of infection and to compare EVs in drug sensitive and resistance isolates and differentiate between liver and rumen fluke.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BBC Wales Scientific Cafe Contribution</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0042585B-4428-4438-AF22-EFB0530562FD</gtr:id><gtr:impact>A variety of conversations/inquires from general public on vaccination for parasitic worm control of livestock

Seeking funding to support a Young farmers visit to IBERS Aberystwyth for a hands-on workshop on parasite control in Livestock</gtr:impact><gtr:outcomeId>54632b9414ac59.06602650</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b04hl1l6</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The Liver fluke parasites (Fasciola hepatica and Fasciola gigantica) impose a major economic and welfare burden on
livestock globally; F. gigantica is one of the most important animal parasites in tropical regions and F. hepatica within
temperate regions. Specifically, to the remit of this programme call, F. gigantica inflicts very significant losses of livestock in India, with infection levels reaching 55% in some regions. Recently estimated costs for liver fluke induced losses
associated with livestock in India fall within the range of US$1.95-4.78 billion per year. This is a huge burden to the largely agricultural Indian economy and directly impacts the productivity of large and small farm holdings alike, negatively
impacting individual farmers and their families. Liver fluke infected buffalo show reduction in general health, weight gain,
feed conversion efficiency and reproduction. The infective worm stage encysts on vegetation such that host animals
inadvertently consume the cysts during grazing. Once in the gut, the juvenile worms hatch, burrow through the gut wall
and penetrate the liver, ending up as adult worms in bile ducts where they feed on host blood, significantly diminishing the
health of the animal and greatly reducing agricultural productivity. In the developed world liver fluke is mainly controlled using the chemical triclabendazole (TCBZ). This drug is an Achilles heel of liver fluke control as it is the only drug that kills both the adult and pathogenic juvenile stages of the parasite. New control strategies are urgently needed as anthelmintic resistance in parasitic worm populations is spreading globally, and agricultural communities in many parts of the developing world simply cannot afford short-lived, anthelmintic-based treatment options. Therefore, there is an urgent need to develop a cost effective, single-treatment control strategy based on vaccination. Numerous liver fluke vaccine trials have been completed and although some success was reported, none have provided protection levels adequate for commercialization. This three year international collaboration between laboratories in India and the UK incorporated new fast throughput nucleotide and protein technologies to reveal new vaccine antigen candidates and also identified a new approach to develop vaccines via dampening the ability of the parasite to suppress the immune system of livestock. The programme addressed the mission of the BBSRC, including treatment of diseases of livestock, application of new technologies and international collaboration. Field trial vaccine approaches are now required to catalyse the launch of the first commercial vaccine for treating liver fluke disease, and this technology strategy is directly transferable to other worm parasites, especially F. hepatica, that is increasing in UK livestock.</gtr:description><gtr:exploitationPathways>Parasitic helminths are a major threat to global food security, and have been estimated to cost the livestock industry worldwide more than $50 billion/annum. The treat-all application approach of broad-spectrum anthelmintics has been the primary method to control parasitic worms in livestock in the developed world for over 50 years, and has made the production of cheap and plentiful food to a growing world population feasible. New control strategies are urgently needed as anthelmintic resistance in parasitic worm populations is spreading globally, and this coupled to the lack of new anthelmintics, means that in some parts of the developed world intensive livestock farming will no longer be sustainable. In addition, agricultural communities in many parts of the developing world simply cannot afford short-lived anthelmintic based treatment strategies and therefore, also urgently require a cost effective single treatment such as anti-worm vaccines. This programme discovered and validated a new approach to support liver fluke vaccination by targeting the parasite's immune modulation machinery delivered by extracellular vesicles to host cells. Vaccine trials with the immune modulator (Sigma GST-Prostaglandin synthase) reported a reduction in pathology in vaccinated livestock. The findings have been reported in two publications and data presented at scientific conference and to the general public (University Open, visit days and BBC radio). Further funding to improve the vaccine formulation is being sought (two BBSRC applications, FADH with Indian collaborators and sLola with new UK collaborators were not funded). However, the data is available to others to exploit for fluke and other worm based vaccine research. The programme also delivered gene discovery in tropical liver fluke via producing a transcriptome of juvenile stage and the dataset will be released for other academics and industr to support their vaccine discovery programmes once publication accepted. Publications from the programme detailing the expression of vaccine candidates from major fluke superfamilies will provide support for other academics and industry to develop their vaccination strategies.</gtr:exploitationPathways><gtr:id>88F4498D-7244-4F19-B432-C70F6F7E2BD5</gtr:id><gtr:outcomeId>545b76bcf18180.84093207</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>New sequences of immuno-suppressor and vaccine candidates were posted by Aberystwyth in public access databases
(NCBI Genbank).
a) F. gigantica Sigma GST GenBank: AFX98103.1
b) F. gigantica Omega GST GenBank: AFX98105.1
c) F. hepatica Omega GST GenBank: AFX98104.1
d) F. hepatica Cathepin L1D GenBank: ACJ12894.1
Additional vaccine candidate sequences will be deposited by Aberystwyth post publication on Fatty acid binding protein
(FABP) superfamily (Morphew et al. In Prep)
a) F. gigantica FABP IV
b) F. gigantica FABP V
c) F. gigantica FABP VI
d) F. gigantica FABP VII
e) F. hepatica FABP IV
f) F. hepatica FABP V
g) F. hepatica FABP VI
h) F. hepatica FABP VII</gtr:description><gtr:id>FB9F266A-1BA5-4C16-9AF3-DC26C4ED6D3F</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>545b88e3a21005.54238249</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Sequences Vaccine candidates Fasciola hepatica</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>The 1.6 Angstrom structure of an immune-suppressor vaccine candidate was lodged by Aberystwyth and collaborator
(Exeter University, UK) in public access databases (NCBI Structure)
 F. hepatica Sigma GST PDB: 2WDU</gtr:description><gtr:id>4EB13D92-8924-42A1-96AD-0070E76CC689</gtr:id><gtr:impact>Not as yet</gtr:impact><gtr:outcomeId>545b893c63ca53.96595006</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>crystal structure vaccine candidate Fasciola hepatica</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The transcriptome of newly excysted juveniles (NEJs) from Fasciola gigantica was determined in order support the research community
by providing gene discovery and protein identification databases</gtr:description><gtr:id>3A8D59E0-5F31-4406-83CB-8FBE2E5D512F</gtr:id><gtr:impact>Data not published as yet.</gtr:impact><gtr:outcomeId>545b87fe5a0a49.87645904</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>transcriptomic database</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New Methodology: Proteomics methodologies have been developed to study major protein superfamilies in liver fluke (and
other organisms): GSTs (Morphew et al. 2012 ) , Cathepsin L (Morphew et al. 2011) and FABPs (Morphew et al. in
preparation).</gtr:description><gtr:id>FCAF8719-5C1F-4C70-A858-093C652CA5E2</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>545b877819a2b0.84270016</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Sub-Proteomics Technologies</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Vaccine candidates: As part of the agreed CIDLID programme Aberystwyth produced recombinant proteins (with storage plasmid clones) and polyclonal antibodies to a number of project identified liver fluke vaccine candidates. Recombinant forms of Sigma, Omega and Mu Class Glutathione transferases (GSTs), fatty acid binding proteins (FABPs) IV, V, VI and VII, Thioredoxin glutathione transferase and Leucine aminopeptidase were produced and polyclonal antisera raised to these proteins. All recombinant proteins have been produced for both F. hepatica and F. gigantica. These reagents are available to the research community.</gtr:description><gtr:id>87ED8877-BA7F-4B6A-A4AD-59A6E2E19C73</gtr:id><gtr:impact>Liver fluke Vaccine trials in buffalo in India and goats in Spain</gtr:impact><gtr:outcomeId>545b8703160237.46049155</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Vaccine candidates for liver fluke</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BFCBFC24-20CB-410E-B373-46FCE61F637E</gtr:id><gtr:title>Calmodulin disruption impacts growth and motility in juvenile liver fluke.</gtr:title><gtr:parentPublicationTitle>Parasites &amp; vectors</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/589d1ce88b389cb014e0c56c1dbbd385"><gtr:id>589d1ce88b389cb014e0c56c1dbbd385</gtr:id><gtr:otherNames>McCammick EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-3305</gtr:issn><gtr:outcomeId>56dd6f2cac9bf2.25041259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>538C908A-DA0F-4D12-BBAE-6D3A854FFDBA</gtr:id><gtr:title>Major secretory antigens of the helminth Fasciola hepatica activate a suppressive dendritic cell phenotype that attenuates Th17 cells but fails to activate Th2 immune responses.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68f36feb4d603388cf5718652f0f9c52"><gtr:id>68f36feb4d603388cf5718652f0f9c52</gtr:id><gtr:otherNames>Dowling DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>5463aa696be999.61095233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49F9C644-87CA-4DF3-882C-DAEC07076CD1</gtr:id><gtr:title>Towards delineating functions within the fasciola secreted cathepsin l protease family by integrating in vivo based sub-proteomics and phylogenetics.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6546cbff8fcab8f4f9d881295e2cab6"><gtr:id>d6546cbff8fcab8f4f9d881295e2cab6</gtr:id><gtr:otherNames>Morphew RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>545b7ce0805c37.78221014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC900B13-514A-4E27-BB21-37ED3CA83322</gtr:id><gtr:title>Time-dependent tegumental surface changes in juvenile Fasciola gigantica in response to triclabendazole treatment in goat.</gtr:title><gtr:parentPublicationTitle>Acta tropica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3888ce323f15b027d1b92a1c2f4d9802"><gtr:id>3888ce323f15b027d1b92a1c2f4d9802</gtr:id><gtr:otherNames>Shareef PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-706X</gtr:issn><gtr:outcomeId>545b79fae7c385.38582998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92200B7E-30C2-4EE3-A13E-04F8A71EC6A0</gtr:id><gtr:title>Early hepatic and peritoneal changes and immune response in goats vaccinated with a recombinant glutathione transferase sigma class and challenged with Fasciola hepatica.</gtr:title><gtr:parentPublicationTitle>Research in veterinary science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef9275165e2e88e0addd3b86cd3f960a"><gtr:id>ef9275165e2e88e0addd3b86cd3f960a</gtr:id><gtr:otherNames>Zafra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0034-5288</gtr:issn><gtr:outcomeId>545b7a95421487.84937571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F30B3F8-E9EA-4087-96B2-CC49542F059B</gtr:id><gtr:title>Proteomic analysis of embryonic Fasciola hepatica: characterization and antigenic potential of a developmentally regulated heat shock protein.</gtr:title><gtr:parentPublicationTitle>Veterinary parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d211e259e370221bb4f66ff5a949fb2e"><gtr:id>d211e259e370221bb4f66ff5a949fb2e</gtr:id><gtr:otherNames>Moxon JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0304-4017</gtr:issn><gtr:outcomeId>5463a71b999bb8.77012929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3F2EA0B-EA83-4878-9B0C-00A49CA22D3E</gtr:id><gtr:title>Anthelmintic metabolism in parasitic helminths: proteomic insights.</gtr:title><gtr:parentPublicationTitle>Parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/171c406f8f544a407a8a9dbb3532af13"><gtr:id>171c406f8f544a407a8a9dbb3532af13</gtr:id><gtr:otherNames>Brophy PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0031-1820</gtr:issn><gtr:outcomeId>545b7d4a146417.21860829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F1301C7-8BB5-462E-B12C-E409DBAFF219</gtr:id><gtr:title>Identification of the major proteins of an immune modulating fraction from adult Fasciola hepatica released by Nonidet P40.</gtr:title><gtr:parentPublicationTitle>Veterinary parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6546cbff8fcab8f4f9d881295e2cab6"><gtr:id>d6546cbff8fcab8f4f9d881295e2cab6</gtr:id><gtr:otherNames>Morphew RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0304-4017</gtr:issn><gtr:outcomeId>545b7ece4b52b0.07512756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7B4CC61-1711-40F5-8A1D-1CEB0689514A</gtr:id><gtr:title>Exploring and Expanding the Fatty-Acid-Binding Protein Superfamily in Fasciola Species.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6546cbff8fcab8f4f9d881295e2cab6"><gtr:id>d6546cbff8fcab8f4f9d881295e2cab6</gtr:id><gtr:otherNames>Morphew RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>585d378be55b90.20912998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA67CFAB-9570-4072-8743-A8336871F490</gtr:id><gtr:title>Proteomics and in silico approaches to extend understanding of the glutathione transferase superfamily of the tropical liver fluke Fasciola gigantica.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6546cbff8fcab8f4f9d881295e2cab6"><gtr:id>d6546cbff8fcab8f4f9d881295e2cab6</gtr:id><gtr:otherNames>Morphew RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>545b7abf2c51b6.50950689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB58D352-49C9-43F0-85B4-4018B99B2392</gtr:id><gtr:title>Immune responses directed at egg proteins during experimental infection with the liver fluke Fasciola hepatica.</gtr:title><gtr:parentPublicationTitle>Parasite immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d211e259e370221bb4f66ff5a949fb2e"><gtr:id>d211e259e370221bb4f66ff5a949fb2e</gtr:id><gtr:otherNames>Moxon JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0141-9838</gtr:issn><gtr:outcomeId>5463a821329c12.93686270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7784722A-3C18-4126-A3D8-368A90E0DC16</gtr:id><gtr:title>RNAi dynamics in Juvenile Fasciola spp. Liver flukes reveals the persistence of gene silencing in vitro.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/157f15988d4a87c1742f6ae93c3f11b3"><gtr:id>157f15988d4a87c1742f6ae93c3f11b3</gtr:id><gtr:otherNames>McVeigh P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>545b79bca411f8.56356650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7911E069-05EC-43BE-B37A-9EEC69BEEB50</gtr:id><gtr:title>The Sigma class glutathione transferase from the liver fluke Fasciola hepatica.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32c5a67a678a10127bacef681c3dbc1c"><gtr:id>32c5a67a678a10127bacef681c3dbc1c</gtr:id><gtr:otherNames>LaCourse EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>545b7aeb8d3ba9.97239721</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/H009256/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>